Sprache auswählen
CNR2
CNR2 Molekülinformation
| Englischer Name | Cannabinoid CB2 receptor | Anzahl der inverkehr gebrachten Arzneimittel | 2 |
| Anzahl der klinischen Arzneimittel | 29 | Target-Alias | CX5，CNR2，CB-2，Cannabinoid Receptor 2，Cannabinoid Receptor 2 (Macrophage)，CB2，Testis-Dominant CNR2 Isoform CB2，CB2A，CB2B，HCB2，Receptor， Cannabinoid， CB2 |
| Höchste Forschungs- und Entwicklungsphase | Approved | ||
| Englischer Name | Cannabinoid CB2 receptor |
| Target-Alias | CX5，CNR2，CB-2，Cannabinoid Receptor 2，Cannabinoid Receptor 2 (Macrophage)，CB2，Testis-Dominant CNR2 Isoform CB2，CB2A，CB2B，HCB2，Receptor， Cannabinoid， CB2 |
| Anzahl der inverkehr gebrachten Arzneimittel | 2 |
| Anzahl der klinischen Arzneimittel | 29 |
| Höchste Forschungs- und Entwicklungsphase | Approved |
CNR2 Produktliste
- Attribut
Protein (1)
- Produktbibliothek
Online (1)
- Spezies
Human (1)
- Etikett
- (1)
- Marker
Unconjugated (1)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
CN2-H52P6 |  Human | HEK293 | Human CNR2 Full Length Protein (VLP) |  |  In den Warenkorb legen |
Gesamtmenge1
- 1
CNR2 Molekülhintergrund
CNR2 (also known as cannabinoid receptor type 2, CB2) is a G protein-coupled receptor from the cannabinoid receptor family that in humans is encoded by the CNR2 gene. It is closely related to the cannabinoid receptor type 1 (CB₁), which is largely responsible for the efficacy of endocannabinoid-mediated presynaptic-inhibition, the psychoactive properties of tetrahydrocannabinol (THC), the active agent in cannabis, and other phytocannabinoids (plant cannabinoids). The principal endogenous ligand for the CB₂ receptor is 2-Arachidonoylglycerol (2-AG).
CNR2 Molekülalias
CNR2,cannabinoid receptor 2,CB2,CX5,CB-2,hCB2
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Ajulemic acid | HU-239; CPL-7075; CT-3; JBT-101; DMH-THC-11-OIC; DMH-11C; IP-751 | Phase 3 Clinical | Corbus Pharmaceuticals Holdings Inc | Cystic Fibrosis; Dermatomyositis; Lupus Erythematosus, Systemic; Lupus Vulgaris; Scleroderma, Diffuse | Details |
| Dronabinol(AXIM Biotechnologies) | Phase 3 Clinical | Axim Biotechnologies Inc | Anorexia Nervosa; Cachexia; Child Nutrition Disorders; Nausea; Neoplasms; Nutrition Disorders; Sarcopenia; Vomiting | Details | |
| Cannabidiol soft-gel (Avecho Biotechnology) | CBD-TPM | Phase 3 Clinical | Avecho Biotechnology Ltd | Sleep Initiation and Maintenance Disorders | Details |
| Cannabidiol Gel (Zynerba) | ZYN002; ZYN-002 | Phase 3 Clinical | Zynerba Pharmaceuticals Inc | DiGeorge Syndrome; Fragile X Syndrome | Details |
| Dronabinol（Vertanical） | VER-01 | Phase 3 Clinical | Vertanical GmbH | Low Back Pain | Details |
| cannabidiol (Cardiol Therapeutics) | Phase 3 Clinical | Cardiol Therapeutics Inc | Cardiovascular Diseases; Coronavirus Disease 2019 (COVID-19); Myocarditis; Pericarditis | Details | |
| Vicasinabin | RG-7774; RO-6868847 | Phase 2 Clinical | F. Hoffmann-La Roche Ag | Diabetic Retinopathy | Details |
| Etrinabdione | VCE-004; EHP-101; VCE-004.8 | Phase 2 Clinical | Emerald, Vivacell Biotechnology | Multiple Sclerosis, Relapsing-Remitting; Peripheral Arterial Disease; Scleroderma, Diffuse | Details |
| ART-2713 | NEO-1940; ART-2713; ART27.13; AZD-1940 | Phase 2 Clinical | Astrazeneca Plc, Neomed Inc, Pfizer Inc | Anorexia; Cachexia; Low Back Pain; Pain; Weight Loss | Details |
| Cannabidiol (Ananda Scientific) | A-1002-N5S; A1002N5S | Phase 2 Clinical | Ananda Scientific Inc | Chronic Pain; Opioid-Related Disorders; Stress Disorders, Post-Traumatic; Tobacco Smoking; Tobacco Use Disorder | Details |
| Cannabidiol (Biopharmaceutical Research Company) | BRC-001 | Phase 2 Clinical | Biopharmaceutical Research Company | Breast Neoplasms; Carcinoma, Ductal, Breast | Details |
| C20T5 | C20T5 | Phase 2 Clinical | Murdoch Childrens Research Institute | Details | |
| C12T12 | C12T12 | Phase 2 Clinical | Murdoch Childrens Research Institute | Details | |
| Beta-Caryophyllene | Phase 2 Clinical | Hartford Hospital | Pain | Details | |
| NTRX-07 | MDA7; NTRX-07; MDA-7 | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Alzheimer Disease; Cognitive Dysfunction; Neuralgia | Details |
| CNTX-6016 | CNTX-6016 | Phase 1 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Chronic Pain; Diabetic Neuropathies; Nociceptive Pain; Pain | Details |
| ZYN-001 | ZYN-001 | Phase 1 Clinical | Zynerba Pharmaceuticals | Fibromyalgia; Neuralgia | Details |
| Cannabidiol/hydroxychloroquine | IHL-675A; IHL-675 | Phase 1 Clinical | Incannex Healthcare Ltd | Arthritis, Rheumatoid; Respiratory Distress Syndrome, Adult | Details |
| Cannabidiol (Artelo Biosciences) | ART-12.11; ART12.11; ART-1211 | Phase 1 Clinical | Artelo Biosciences Inc | Anxiety; Depression; Depressive Disorder | Details |
| AAT-730 | AAT-730; RQ-00202730; OCT-461201 | Phase 1 Clinical | Pfizer Holding France Farevaamboise | Diabetic peripheral neuropathy; Irritable Bowel Syndrome; Neuralgia; Neuralgia, Postherpetic; Pain; Peripheral Nervous System Diseases | Details |
| S1-221 | S1-221 | Phase 1 Clinical | Delphian Therapeutics Australia Pty Ltd | Details | |
| Cannabidiol (Tiamat Australia) | MRX-1 | Phase 1 Clinical | Tiamat Australia Pty Ltd | Details | |
| Atorvastatin Calcium Hydrate/Cannabidiol | Phase 1 Clinical | Indication Bioscience LLC | Coronary Disease; Dyslipidemias | Details | |
| [18F]-RoSMA-18-d6 | Phase 1 Clinical | Eth Zurich | Amyotrophic Lateral Sclerosis | Details | |
| IPI 201（Isosceles Pharmaceuticals Inc ） | IPI-201 | Phase 1 Clinical | Pain, Postoperative | Details | |
| Onternabez | PPP-003; HU-308; ARDS-003 | Phase 1 Clinical | Hebrew University, University Of Aberdeen | Coronavirus Disease 2019 (COVID-19); Ocular inflammation; Pain; Respiratory Distress Syndrome, Adult; Retinal Diseases; Sepsis; Uveitis; Virus Diseases; Xerophthalmia | Details |
| MP-10X | MP-10X | Clinical | Medipure Holdings | Pain | Details |
| Cannabidiol (Receptor Life Sciences) | Clinical | Receptor Life Sciences Inc | Autism Spectrum Disorder | Details | |
| Cannabidiol/Palmitoylethanolamide | SCI–210; THX-210 | Clinical | Therapix Biosciences Ltd | Autism Spectrum Disorder; Diabetic Neuropathies | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Cannabidiol/Dronabinol | delta-9-THC/CBD; MPL-001; MPL-005; PPP-011; BOL-DP-o-04; GW-1000-02; PPP-001; MGC-ODT; GW-1000; KL16-012; THC-5 | Approved | Gw Pharmaceuticals | Sativex, Qixleef, QIXLEEFTM | Canada | Cancer Pain; Chronic Pain; Muscle Spasticity; Neuralgia; Multiple Sclerosis | null | 2005-04-01 | Acute Pain; Agitation; Agoraphobia; Anorexia; Anxiety Disorders; Arthritis, Psoriatic; Arthritis, Rheumatoid; Back Pain; Cancer Pain; Cerebral Palsy; Chronic Pain; Corticobasal degeneration; Dementia; Depression; Depressive Disorder, Major; Diabetic Neuropathies; Drug Resistant Epilepsy; Essential Tremor; Genital Diseases, Male; Healthy Aging; Hepatic Insufficiency; Hidradenitis Suppurativa; Huntington Disease; Kidney Diseases; Low Back Pain; Malnutrition; Marijuana Abuse; Marijuana Use; Migraine Disorders; Multiple Sclerosis; Muscle Spasticity; Neck Pain; Neoplasms; Neuralgia; Neuralgia, Postherpetic; Neuromyelitis Optica; Opioid-Related Disorders; Osteoarthritis, Knee; Pain; Panic Disorder; Peripheral Nervous System Diseases; Phobia, Social; Psoriasis; Reflex Sympathetic Dystrophy; Renal Insufficiency; Renal Insufficiency, Chronic; Sciatica; Sleep Initiation and Maintenance Disorders; Sleep Wake Disorders; Social Behavior; Spasm; Spinal Cord Injuries; Squamous Cell Carcinoma of Head and Neck; Stress Disorde | Details |
| Cannabidiol | CHI-902; APH-1501; GLA-015; BTX-1503; BTX-1801; GWP-42003-P; BOL-DP-o-05; GW-42003; BTX-1204; PTL-101; BTX-1702; PBX-1308; BRCX-014; LYT-310; GWP-42003 | Approved | Gw Pharmaceuticals Plc | Epidyolex, Cannepil, Epidiolex | United States | Epilepsies, Myoclonic; Lennox Gastaut Syndrome | null | 2018-06-25 | Acne Vulgaris; Acute Pain; Alcohol Abstinence; Alcoholic Intoxication; Alcoholism; Anemia, Sickle Cell; Anorexia Nervosa; Anxiety; Anxiety Disorders; Appetitive Behavior; Arthralgia; Arthritis, Psoriatic; Arthritis, Rheumatoid; Autism Spectrum Disorder; Autistic Disorder; Azotemia; Behavior, Addictive; Bipolar Disorder; Blepharospasm; Brain Diseases; Brain Injuries, Traumatic; Breast Neoplasms; Bruxism; Burnout, Psychological; Cachexia; Carcinoma, Non-Small-Cell Lung; Carpal Tunnel Syndrome; Central Nervous System Diseases; Child Behavior Disorders; Chronic Pain; Chronic Periodontitis; Chronic Urticaria; Cicatrix; Cognition Disorders; Cognitive Dysfunction; Colitis, Ulcerative; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Corticobasal degeneration; Craving; Crohn Disease; Cystitis, Interstitial; Dentin Sensitivity; Depression; Dermatitis, Atopic; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Driving Under the Influence; Drug Resistant Epilepsy; Dyslipidemias; Dysmenorrhea; Dyspepsia; Eczema; | Details |
- Molekülinformation
- Produktliste
- Inverkehr gebrachte Arzneimittelinformation
- Klinische Arzneimittelinformation
Teilen auf:
Online-Nachricht
Kontaktieren Sie uns
BettinastraBe 30, 60325 Frankfurt am Main